Abstract: The present invention provides a composition for measuring the gastric-emptying function and a method for measuring the gastric-emptying function effectively usable in diagnosing dyspepsia. The present invention also provides a dyspepsia diagnostic agent, a method for diagnosing dyspepsia, and a method for measuring the treatment effect on a patient suffering from gastrointestinal disorders caused by insufficiencies in the gastric-emptying function (including a pharmacotherapy). One of the main features of the composition for measuring the gastric-emptying function of the present invention is that a pyrimidine compound, which is converted to a labeled CO2 gas in the body and excreted in expired air, labeled with an isotope of C or O, is used as an active ingredient. The method of the present invention can be conducted by orally administering the composition to a subject, and measuring the amount or behavior of the labeled CO2 excreted in expired air.

Abstract: The present invention provide a method for measuring and assessing the capacity in an individual subject to metabolize a variety of fluorouracil drugs, such as 5-fluorouracil, which are degraded in the pyrimidine metabolic pathway, and a preparation useful for the measurement and assessment. The present invention can be carried out by: administering a preparation for determining pyrimidine metabolic capacity comprising as an active ingredient a pyrimidine compound or pyrimidine metabolic compound that acts as a substrate for a pyrimidine metabolizing enzyme, in which at least one of the carbon, oxygen, and nitrogen atoms is labeled with an isotope; and assessing in vivo pyrimidine metabolic capacity based on the behavior of an excreted metabolite.

Abstract: Preparations whereby reduction or acceleration of the gastric emptying rate can be noninvasively evaluated: and a method of evaluating the gastric emptying rate by using these preparations. Thus, reduction or acceleration of the gastric emptying rate can be safely and conveniently examined. Namely, theses preparations are useful in objectively diagnosing the gastric motor function, as well as in evaluating and judging the drug effect or therapeutic effect of a drug concerning the gastric motor function on individual patients.

Abstract: Preparations whereby reduction or acceleration of the gastric emptying rate can be noninvasively evaluated: and a method of evaluating the gastric emptying rate by using these preparations. Thus, reduction or acceleration of the gastric emptying rate can be safely and conveniently examined. Namely, theses preparations are useful in objectively diagnosing the gastric motor function, as well as in evaluating and judging the drug effect or therapeutic effect of a drug concerning the gastric motor function on individual patients.

Abstract: The present invention provide a method for assessing the sensitivity to a pyrimidine drug such as 5-FU which is degraded in the pyrimidine metabolic pathway, specifically in vivo pyrimidine metabolizing activity, of an individual subject; and a preparation useful for the assessment. The present invention can be carried out by: administering a preparation comprising as an active ingredient a pyrimidine compound or its metabolite which acts as a substrate for a pyrimidine metabolizing enzyme, in which compound or metabolite at least one of C, O and N is labeled with an isotope; and assessing in vivo pyrimidine metabolizing activity based on the amount of excreted metabolite.

Abstract: The present invention provide a method for assessing the sensitivity to a pyrimidine drug such as 5-FU which is degraded in the pyrimidine metabolic pathway, specifically in vivo pyrimidine metabolizing activity, of an individual subject; and a preparation useful for the assessment. The present invention can be carried out by: administering a preparation comprising as an active ingredient a pyrimidine compound or its metabolite which acts as a substrate for a pyrimidine metabolizing enzyme, in which compound or metabolite at least one of C, O and N is labeled with an isotope; and assessing in vivo pyrimidine metabolizing activity based on the amount of excreted metabolite.

Abstract: Preparations whereby reduction or acceleration of the gastric emptying rate can be noninvasively evaluated: and a method of evaluating the gastric emptying rate by using these preparations. Thus, reduction or acceleration of the gastric emptying rate can be safely and conveniently examined. Namely, theses preparations are useful in objectively diagnosing the gastric motor function, as well as in evaluating and judging the drug effect or therapeutic effect of a drug concerning the gastric motor function on individual patients.

Abstract: The present invention provides a preparation for easily and non-invasively measuring gastric pH, for example, a preparation for measuring gastric pH using the expired air, and a method for measuring gastric pH using the preparation. The preparation of the present invention can be produced by covering a composition containing a compound labeled with an isotope (13C, 14C, 15N, or 18O), with a pH-dependent soluble base.

Abstract: The present invention provide a method for measuring and assessing the capacity in an individual subject to metabolize a variety of fluorouracil drugs, such as 5-fluorouracil, which are degraded in the pyrimidine metabolic pathway, and a preparation useful for the measurement and assessment. The present invention can be carried out by: administering a preparation for determining pyrimidine metabolic capacity comprising as an active ingredient a pyrimidine compound or pyrimidine metabolic compound that acts as a substrate for a pyrimidine metabolizing enzyme, in which at least one of the carbon, oxygen, and nitrogen atoms is labeled with an isotope; and assessing in vivo pyrimidine metabolic capacity based on the behavior of an excreted metabolite.

Abstract: The present invention provide a method for assessing the sensitivity to a pyrimidine drug such as 5-FU which is degraded in the pyrimidine metabolic pathway, specifically in vivo pyrimidine metabolizing activity, of an individual subject; and a preparation useful for the assessment. The present invention can be carried out by: administering a preparation comprising as an active ingredient a pyrimidine compound or its metabolite which acts as a substrate for a pyrimidine metabolizing enzyme, in which compound or metabolite at least one of C, O and N is labeled with an isotope; and assessing in vivo pyrimidine metabolizing activity based on the amount of excreted metabolite.

Abstract: There is provided a diagnostic for central nervous abnormality, comprising a labeled transmitter substance of central nervous system or a labeled precursor of the transmitter substance, whose at least one of carbon atoms is substituted for a carbon isotope wherein the diagnostic is useful for diagnosing a central nervous abnormality (e.g. depression, Alzheimer's disease, schizophrenia, etc.) by applying it to a living body by oral administration or injection and examining a change in an amount of the carbon isotope in a breath of the living body.

Abstract: An antibody of a human leukemia virus-related peptide obtained by collecting an antibody produced in a mammal body by administering to the mammal an antigen prepared by reacting a human leukemia virus-related peptide represented by formula (1):R-Pro-Val-Met-His-Pro-His-Gly-Ala-Pro-OH (1)whereinR is a hydrogen atom or a group shown by formula, H-Tyr-;as a hapten, with a carrier in the presence of a hapten-carrier binding agent.